Categories
Change Password!
Reset Password!
A single dose of suraxavir marboxil cut flu recovery time by 21 hours and accelerates viral clearance with an acceptable safety and resistance profile in uncomplicated influenza.
Results from a phase 3 randomized trial published in ‘Nature Medicine’ indicated that a single 40 mg administration of suraxavir marboxil notably reduced the duration of the flu and enhanced viral clearance in healthy individuals between the ages of 5 and 65.
Suraxavir marboxil (GP681) is an antiviral targeting the polymerase acidic protein (PA), a critical enzyme in influenza virus replication. Earlier preclinical investigations have revealed its effectiveness against both influenza A and B viruses. The study under consideration was conducted across 46 research centres in China from July 2022 to October 2023. A total of 591 patients with uncomplicated influenza were enrolled and randomly assigned in a 2:1 ratio to receive either suraxavir marboxil or a placebo within 48 hours of symptom onset.
The primary outcome, time to symptom alleviation, was fever resolution (≤37.2°C) and relief of cough, pharyngitis (sore throat), headache, nasal congestion, feverishness/chills, muscle/joint pain, and tiredness for 21.5+ hours. Secondary endpoints comprised viral load, respiratory symptoms, mutations in the PA and safety.
Major Findings:
With a single dose delivering faster symptom relief and viral suppression, suraxavir marboxil presents a promising new option for flu treatment. Its rapid action, ease of administration, and favourable safety profile could position it as a potential game-changer in influenza management.
Nature Medicine
Single-dose Suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Yeming Wang et al.
Comments (0)